Regulations Needed to Improve Clinical Adoption Of CBD as Medicine
There must be clear rules and regulations in effect if we are to see medical-grade CBD become widely accepted amongst clinicians.
Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program
Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.
presented by
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
Taking the fun out of weed, but addressing unmet need: Startup refining cannabinoids for therapeutic use
Los Angeles startup Kalytera Therapeutics is taking the high out of the THC – refining cannabinoids so they can have broader therapeutic applications in conditions like osteoporosis, Prader-Willi syndrome, PTSD, obesity and weight loss associated with cancer. Kalytera just raised $500,000 in seed funding, according to a regulatory filing. There’s a litany of potential applications for […]